Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
User-agent: * Disallow: /wp-admin/ Allow: /wp-admin/admin-ajax.php Sitemap: |
Title | Aptarion |
Description | APTARION BIOTECH About us Programs People Finance Technology Publications News APTARION BIOTECH AG WE DEVELOP INNOVATIVE DRUGS FOR LIFE-THREATENING DISEASES. Learn more Se |
Keywords | N/A |
WebSite | aptarion.com |
Host IP | 217.160.0.52 |
Location | Germany |
Site | Rank |
US$1,819,019
Last updated: 2023-05-10 12:46:30
aptarion.com has Semrush global rank of 5,818,688. aptarion.com has an estimated worth of US$ 1,819,019, based on its estimated Ads revenue. aptarion.com receives approximately 209,887 unique visitors each day. Its web server is located in Germany, with IP address 217.160.0.52. According to SiteAdvisor, aptarion.com is safe to visit. |
Purchase/Sale Value | US$1,819,019 |
Daily Ads Revenue | US$1,680 |
Monthly Ads Revenue | US$50,373 |
Yearly Ads Revenue | US$604,474 |
Daily Unique Visitors | 13,993 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
aptarion.com. | A | 3599 | IP: 217.160.0.52 |
aptarion.com. | AAAA | 3599 | IPV6: 2001:8d8:100f:f000::227 |
aptarion.com. | NS | 86400 | NS Record: ns1077.ui-dns.org. |
aptarion.com. | NS | 86400 | NS Record: ns1077.ui-dns.biz. |
aptarion.com. | NS | 86400 | NS Record: ns1077.ui-dns.de. |
aptarion.com. | NS | 86400 | NS Record: ns1077.ui-dns.com. |
aptarion.com. | MX | 3600 | MX Record: 10 aptarion-com.mail.protection.outlook.com. |
aptarion.com. | TXT | 3600 | TXT Record: MS=ms20158709 |
aptarion.com. | TXT | 3600 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
About us Programs People Finance Technology Publications News APTARION BIOTECH AG WE DEVELOP INNOVATIVE DRUGS FOR LIFE-THREATENING DISEASES. Learn more Send mail About us Aptarion Biotech AG is a clinical-stage drug development company leveraging the unique properties of mirror-image (L-) aptamers. L‑Aptamers are single-stranded L-RNA or L-DNA molecules combining high target affinity, specificity and biostability with the ease of a scalable chemical production process. Our lead program AON-D21 has completed Phase 1 clinical development. The first trial in patients shall commence in 2023. AON-D21 neutralizes complement factor C5a, a central player of the immune system. C5a is believed to trigger excessive immune responses in severe inflammatory diseases and infections, and to be involved in immune evasion mechanisms of tumors. Aptarion is headquartered in Berlin, Germany. About us Programs People Finance Technology Publications News © 2023 APTARION Biotech AG Imprint Privacy Policy To |
HTTP/1.1 200 OK Content-Type: text/html Content-Length: 1054 Connection: keep-alive Keep-Alive: timeout=15 Date: Tue, 02 Nov 2021 19:10:26 GMT Server: Apache Last-Modified: Wed, 30 Aug 2017 13:50:23 GMT ETag: "41e-557f8cf2ea5c0" Accept-Ranges: bytes |
Domain Name: APTARION.COM Registry Domain ID: 2037062602_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.ionos.com Registrar URL: http://www.ionos.com Updated Date: 2021-06-24T07:06:41Z Creation Date: 2016-06-23T08:04:02Z Registry Expiry Date: 2022-06-23T08:04:02Z Registrar: 1&1 IONOS SE Registrar IANA ID: 83 Registrar Abuse Contact Email: abuse@ionos.com Registrar Abuse Contact Phone: +1.6105601459 Domain Status: ok https://icann.org/epp#ok Name Server: NS1077.UI-DNS.BIZ Name Server: NS1077.UI-DNS.COM Name Server: NS1077.UI-DNS.DE Name Server: NS1077.UI-DNS.ORG DNSSEC: unsigned >>> Last update of whois database: 2021-09-23T09:27:56Z <<< |